Please login to the form below

Not currently logged in
Email:
Password:

quarterly sales

This page shows the latest quarterly sales news and features for those working in and with pharma, biotech and healthcare.

Biogen files Tecfidera follow-up in the US

Biogen files Tecfidera follow-up in the US

The tolerability issue hasn’t held back Tecfidera commercially, however, with quarterly sales currently running at more than $1bn, despite tougher competition overall in the MS market.

Latest news

  • Generic threat looms to J&J’s blockbuster Zytiga in US Generic threat looms to J&J’s blockbuster Zytiga in US

    launches. The importance of Zytiga to J&J at the moment can’t really be overstated: its  quarterly sales are nearly $1bn – well over half from the US – and growing at ... Zytiga will enter the market and will result in a significant decline in

  • AZ agrees to $320m deal for Zoladex AZ agrees to $320m deal for Zoladex

    products. The deal, which is expected to close by the end of March, will see AZ receive a $250m upfront payment for the rights, with double-digit quarterly sales-based payments ... ongoing. A further $70m is also up for grabs should Zoladex (goserelin

  • GSK's Witty ends on a high, but warns 2017 looking 'uncertain' GSK's Witty ends on a high, but warns 2017 looking 'uncertain'

    Generic competition to big-selling Seretide/Advair in the US could accelerate sales decline. ... Other generics from Mylan and Hikma are under regulatory review, however, which could be directly substitutable and accelerate the decline in the brand's

  • 2017 set to be a 2017 set to be a "defining year" for AZ

    The last AZ drug to fall over the 'patent cliff' - cholesterol-lowerer Crestor (rosuvastatin) - saw sales cut in half in the fourth quarter after the loss of US patent protection, with ... The decline was, however, offset by good growth for non-small

  • Tecentriq growth offsets Avastin's US decline at Roche Tecentriq growth offsets Avastin's US decline at Roche

    Roche is hoping that while Avastin is likely to see some cannibalisation of sales from Tecentriq, combination use could support its older drug. ... Overall, Roche reported a 3% increase in pharma sales to CHF 39bn, and the company is expecting low- to mid

More from news
Approximately 9 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    At the moment Humira accounts for nearly two-thirds of AbbVie’s total sales. ... The merger was completed shortly after BMS reported the first decline in quarterly sales of its immuno-oncology blockbuster Opdivo (nivolumab) since its launch five years

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

AI and genomics: a revolution in drug discovery and development
...
Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....

Infographics